ABSTRACT PHARMACEUTICAL COMPOSITIONS OF IVERMECTIN AND PROCESS FOR PREPARATION THEREOF The invention relates to a topical pharmaceutical composition comprising effective amount of ivermectin as an active agent, process of preparation thereof and method of treating dermatological conditions such as inflammatory les...

The present invention relates to a process for the preparation of Olmesartan medoxomil of formula (I), which comprises: (i)    condensing ethyl 4-(l -hydroxy-l-methylethyl)-2-propylimidazole-5-carboxylate of   formula   (II),    with    5-[4"-(bromomethyl)[l,l"-biphenyl]-2-yl]-N- (triphenylmethyl)tetrazole of ...

The present invention relates to an improved process for the preparation of dipepetidyl peptidase-IV inhibitor compound of formula I.

ABSTRACT LEVOTHYROXINE COMPOSITIONS AND PROCESSES THEREOF The present invention relates to a lyophilized composition comprising levothyroxine or a salt thereof and the process for preparation thereof. The present invention also relates to lyophilized compositions of levothyroxine that are useful when thyroid rep...

The present invention provides a process for the preparation of Tenofovir disoproxil fumarate (I), which comprises: adding a base to a mixture of (R)-9-[2-(phosphonomethoxy)propyl]adenine (II) and chloromethyl isopropyl carbonate (III) in a solvent and optionally a phase transfer catalyst to produce Tenofovir disopr...

DISC SHAPED DEVICE TO PREVENT ABRASION Device for immobilizing contents in a container and more particularly device and a method for immobilizing solid dosage forms such as pills, tablets, capsules or other breakable contents in containers are provided.

An improved purification process for preparing Crystalline Imipenem monohydrate of Formula I,

The present invention provides a process for the preparation of Duloxetine (I), which comprises: condensing (lS)-3-(methylamino)-l-(thiophene-2-yl)propan-l-ol (V), with 1-fluoronaphthalene in presence of a base, a solvent and a catalyst to produce Duloxetine (I); optionally, Duloxetine (I) is converted to Duloxetine...

The present invention relates to a process for the preparation of Clobazam (I), wherein a compound (Va) is reacted with alkyl malonyl chloride to produce a compound (IVa), which is cyclized to produce N-desmethyl clobazam (IV) followed by N-methylation with methylating agent to obtain Clobazam (I). The present inven...

ABSTRACT A PROCESS FOR THE PREPARATION OF CEFPODOXIME PROXETIL The present invention provides a process for the preparation of pure Cefpodoxime Proxetil (I) or pharmaceutically acceptable salts thereof; by treating Cefpodoxime Proxetil (I) with a biphasic solution comprises a scavenger, water and a water immisci...

The present invention relates* to spray dried granulate of curcuminoids and process for preparation thereof. The spray dried granulates have enhanced aqueous solubility and are useful in the preparation of various pharmaceutical and nutraceutical compositions.

The present invention relates to a process for the preparation of Fosinopril sodium Form A from fosinopril by treating it with sodium metal carrier in the presence of ethyl acetate containing 0.5% to 5% of water.

The present invention relates to nicotine or nicotine polacrilex lozenge compositions comprising nicotine or nicotine derivatives as an active agent and the process for preparation thereof. The present invention also relates to method of using nicotine or nicotine polacrilex lozenge compositions for reducing withdra...

Abstract The technical field of the present invention relates pharmaceutical compositions comprising one or more non-steroidal anti-inflammatory drugs (NSAID) in combination with at least one antihistamine, sympathomimetic drug (nasal decongestant, bronchodilator) cough suppressant and/or expectorant, optionally in...

The present invention relates to an improved process for preparing Rosuvastatin calcium of Formula I

The  present  invention  relates  to  novel  salts  of  (lS,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1 -methanol of Formula I or solvates or hydrates thereof, wherein M represents hemimalonate, malonate, hemioxalate, oxalate, hydrobromide, dihydrobromide, hemimaleate, maleate. ...

The present invention relates to a solid dosage form comprising fenofibrate. The present invention also relates to a process for preparation of solid dosage form comprising fenofibrate.

The present invention relates to a liquid dosage form comprising insoluble and unpleasant active drug and a liquid excipient base. In particular, the invention relates to a liquid dosage form comprising acetaminophen and a liquid excipient base as a solubilizer.

The present invention relates to an improved process for preparing pure Lamivudine of Formula I, which comprises treating Lamivudine (I) with hydrochloric acid to give Lamivudine hydrochloride salt (VIII); optionally isolating Lamivudine hydrochloride salt (VIII), desalifying the Lamivudine hydrochloride salt (VIII)...

The present invention relates to a novel process for preparing a compound of Formula II, which is a useful intermediate in the preparation of Aliskiren.

An improved process for preparing Carbapenem derivatives of Formula I, by traeting the aqueous solution by n-butanol or spray drying.

The present invention relates to an improved process to prepare (S)-5-methoxy-2-[[(4- melhoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole Magnesium Dihydrate Form A of Formula I.

The present invention relates to an improved process for preparing (2E)-3-[2-Cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-2-propenal of Formula I, which is an useful intermediate in the preparation of Pitavastatin calcium.

The present invention relates to a process for the preparation of pure Paliperidone Palmitate, which comprises; (a) providing a solution of Paliperidone Palmitate in an alcoholic solvent; (b) adding the alcoholic solution of Paliperidone palmitate to water or vice versa; and (c) isolating the product to obtain pure ...

The present invention relates to an improved process for the preparation of an optically active indoline derivative of a compound of formula (II), wherein R is hydroxyl protecting group. The compound of formula (II) is the key intermediate in the synthesis Silodosin of a compound of formula (I). ...

The present invention relates to an improved process for the preparation of Etravirine (I) and its intermediates, wherein Des-bromo Etravirine (XI) is purified and this purified form as such used in the next step for the preparation of Etravirine (I). The present invention also relates to purification of Etravirine ...

The present invention relates to an improved process to prepare chiral diol sulfones of formula wherein R| and R2 each independently represent group selected from CM alkyl, CM alkenyl, C3.6 cycloalkyl, C6-io aryl or C7_12 aralkyl, each of R| and R2 may be substituted and wherein Ri and R2 may form a ring together ...

PHARMACEUTICAL COMPOSITIONS COMPRISING DIMETHYL FUMARATE The present invention relates to a delayed release composition comprising multiple enteric . coated tablets comprising less than about 43% w/w of dimethyl fumarate and one or more pharmaceutically acceptable excipients, wherein the tablet diameter is from abo...

The present invention relates to a binder free pharmaceutical composition comprising canagliflozin or a prodrug or a phannaceutically acceptable salt thereof, and one or more pharmaceutical ly  acceptable excipients, wherein the said composition is devoid of canagliflozin hemihydrate, and having acceptable chemical ...

Sterile formulation comprising glucocorticosteroids, process for the preparation of the sterile formulation and method of using the same are provided. The present invention also relates to sterile formulation comprising budesonide, process for the preparation of the sterile formulation and method of using the same. ...

The present invention relates to new polymorphic forms of Ertapenem sodium of Formula I, designated as Form Al, Form A2 and Form A3 and process for preparation thereof.

The technical field of the present invention relates to stable pharmaceutical compositions of angiotensin II antagonists. More particularly, the present invention relates to stable pharmaceutical compositions of candesartan cilexetil.

The present invention provides a process for the preparation of (Z?)-3-amino-l-butanol (I). The present invention also provides (i?)-3-amino-l-butanol (D)-tartarate (lib) salt. The present invention provides a process for the preparation of Dolutegravir using compounds of formulae (I) or (lib) or both. ...

PHARMACEUTICAL FORMULATIONS COMPRISING SILODOSIN The present invention relates to a pharmaceutical composition comprising i) silodosin or a prodrug or a pharmaceutically acceptable salt thereof as the active ingredient, ii) one or more diluents, iii) one or more surfactants, iv) Hydrogenated vegetable oil, and opti...

Stable compositions comprising apixaban are provided. The present invention also relates to process for preparation of such stable compositions comprising apixaban. The present invention also relates to method of using the stable compositions comositions comprising apixaban.

The present invention relates to an oral dosage form comprising an estrogenic compound and process of preparation thereof. Particularly, the present invention relates to an oral dosage form comprising an estrogenic and progestogenic compound. More particularly, the present invention relates to process for the prepar...

The present invention provides a process for the preparation of or-Form crystals of Mirabegron using a solvent selected from water.

The present invention relates to a pharmaceutical ophthalmic suspensión comprising Nepafenac. The present invention fiírther relates to process for the preparation of the suspensión. The present invention fiírther relates to method for the treatment of pain and inflammation associated with cataract surgery using top...

The present invention relates to a liquid formulation for parenteral administration comprising a somatostatin analogue or a pharmaceutically acceptable salt thereof and a buffer other than tartaric acid, process of preparation thereof and method of using the same. Particularly the present invention relates to liqui...

The present invention provides an improved process for the preparation of Dolutegravir (I) or pharmaceutical ly acceptable salts thereof, by reacting 5-methoxy-6-(methoxycarbonyl)-4-oxo-l-(2-oxoethyl)-l,4-dihydro pyridine-3-carboxylic acid (XVI) with an optically active acid addition salt of (i?)-3-amino-l -butanol ...

The present invention relates to a novel process for preparing Pitavastatin calcium salt of formula I.

Pharmaceutical formulation comprising aripiprazole as an active agent or a pharmaceutically acceptable salt thereof, at least one acid other than organic acid, optionally along with one or more pharmaceutically acceptable excipient(s) is provided. The present invention also provides process of preparing such formula...

The present invention relates to oral controlled release compositions comprising potassium chloride. The present invention also relates to improved processt for preparing oral controlled release compositions comprising potassium chloride. The present invention further relates to methods of treatment of hypokalemia w...

The present invention relates to a process for the preparation of Polyquatemium-1; which comprises, treating 1 ,4-bis( dimethylamino )-2-butene-1 ,4 - dichloro-2-butene copolymer with triethanolamine in presence of an alcoholic solvent.

The present invention relates to an improved process for the preparation of Modafinil and its enantiomer of Formula I.

The present invention provides a process for the preparation of Valganciclovir of formula (I) or pharmaceutically acceptable salt thereof, which comprises: (i)    condensing monoacetyl Ganciclovir (XIII) with t-BOC-L-valine to produce acetyl t-BOC Valganciclovir of formula (XVI), (ii)   hydrolyzing the compound of...

ABSTRACT PHARMACEUTICAL COMPOSITION OF MACITENTAN AND PROCESS FOR PREPARATION THEREOF A pharmaceutical composition comprising an endothelin receptor antagonist (ERA) as an active agent, process of preparation thereof and method of using the same are provided. Particularly, the present invention relates to phar...

The present invention relates to a process for preparing sterile ophthalmic suspension of carbonic anhydrase inhibitor. More particularly, the present invention relates to a process for preparing sterile ophthalmic suspension of brinzolamide.

The present invention relates to an improved process to prepare chiral diol suifones of formula I, wherein R1 and R2 each independently represent group selected from C1-4 alkyl, CM alkenyl, C3-6 cycloalkyl, C6.10 aryl or C7.2 aralkyl, each of R1 and R2 may be substituted and wherein R1 and R2 may form a ring togeth...

The present invention relates to solid oral dosage forms of HIV protease inhibitors. More particularly, the present invention relates to solid oral dosage forms comprising ritonavir. The present invention further relates to a process for the preparation of solid oral dosage form comprising ritonavir. ...

AN IMPROVED PROCESS FOR THE PREPARATION OF g,g-DIMETHYL-4-[4-f4-(HYDROXYDIPHENYLMETHYLM-PIPERIDINYL1-1-OXOBUTYL1PHENYL ACETIC ACID ALKYL ESTER The present invention provides a process for preparing a,a-dimethyl-4-[4-[4-(hydroxyl diphenylmethyl)-l-piperidinyl]-l-oxobutyl]phenyl acetic acid alkyl ester of Formula ...

The present invention relates to a solid premix comprising Raltegravir potassium and a pharmaceutically acceptable carrier. The present invention also relates to a process for the preparation of solid premix comprising Raltegravir potassium and a pharmaceutically acceptable carrier.

Novel solvates of Darunavir, wherein the solvate is a glycol or glycol ether.

The present invention relates to a polymorphic form of Atorvastatin calcium of Formula I, as depicted in Figure 1.

The present invention relates to a process for the preparation of Solifenacin succinate by condensing a compound of formula (IVb) with (RS)-3-quinuclidinol, wherein, R represents methyl, ethyl, isopropyl; to produce a diastereomeric mixture of (1 S)-3,4-dihydro-l-phenyl-2(1H)-isoquinolinecarboxylic acid (3RS)-1- ...

The present invention provides a process for the preparation of monobenzyl Ganciclovir (XIII), which comprises, N-acetyl chloro benzyl ganciclovir (III) or its acid addition salt with an alkali acetate in the presence of an acid in a solvent to produce a mixture of diacetyl monobenzyl ganciclovir (XXII) and monoacet...

The present invention provides an improved process for the preparation of Raltegravir of Formula (I); which comprises hydrogenation of compound of Formula (XVII) with a hydrogenation catalyst to produce compound of Formula (XVIII), which is further reacted with compound of Formula (XI) to produce compound of Formul...

The present invention relates to a process for the preparation of pure Valsartan (I) substantially free from impurities of formulae (la), (lb), and (Ic), which comprises: (i)   condensing 2-(4"-bromomethylphenyl)benzonitrile of formula (II) with L-valine methyl ester hydrochloride of formula (V) in the presence of a...

The present invention relates to an improved process for the preparation of Silodosin (I), which comprises by treating l-(3-benzoyloxypropyl)-5-[(2/?)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-lH-indole-7-carbonitrile of a Compound of Formula (II) with N-acetyl-L-glutamatic acid to prod...

1. Crystalline 2-(l -amino-1 -methylethyl)-N-(4-fluoro-benzyl)-5-hydroxy-1 -methyl-6- oxo-l,6-dihydropyrimidine-4-carboxamide (X), characterized by X-ray diffraction spectrum which shows peaks at the diffraction angles of about 7.66 ± 0.2, 9.76 ± 0.2, 9.43 ± 0.2, 10.03 ± 0.2, 10.56 ± 0.2, 12.28 ± 0.2, 12.55 ± 0.2...

The present invention relates to a novel process for the preparation of Meropenem trihydrate of formula I.

The present invention relates to novel organic acid salt of Pitavastatin alkyl ester of Formula I. wherein R represents C1.3 alkyl; X represents monobasic or dibasic acid

The present invention relates to an improved process for the preparation of carbapenem derivatives of formula I, from intermediate compound of formula IV, wherein R1 represnts acetyl group, P1 represents hydrogen or amino protecting group selected from the group consisting of p-nitrobenzyloxycarbonyl and t-but...

The present invention provides a process for the preparation of crystalline Azilsartan kamedoxomil (la), which comprises, treating Azilsartan medoxomil (I) with potassium source in presence of a solvent; isolating the crystalline Azilsartan kamedoxomil (la) from the reaction mixture; optionally purifying the crystal...

AN IMPROVED PROCESS FOR THE PREPARATIONOF DROXIDOPA The present invention relates to an improved process for the preparation of threo-3-(3,4-dihydroxyphenyl)-L-serine commonly known as Droxidopa of a Compound of Formula (1). Formula1

The present application provides an improved process for the preparation of Sildenafil citrate of Formula la, which comprises: (i)    reacting 5-(2-ethoxypheny 1)-1 -methyl-3-n-propyl-1,6-dihydro-7H- pyrazolo[4,3-d]pyramidin-7-one of formula (II), with chlorosulfonic acid in the  presense  of thionyl  chloride  ...

The present invention relates to an improved process for the preparation of amorphous Cilastatin sodium of formula I.

The present invention provides a process for the preparation of 2-clorobenzaldehyde-5-sulfonic acid (IIIa), by reacting orthochlorobenzaldehyde (II) with a sulfonating agent to produce compound of formula (IIIa), purifying the crude compound of formula (IIIa), and isolating pure compound of formula (IIIa), which is ...

The present invention relates to an improved process for the preparation of pure Paliperidone of Formula I.

The present invention relates to an improved process for the preparation of Lacosamide of Formula (I), comprising: O-methylating a compound of Formula (V); in the presence of a methylating agent and a base to produce Lacosamide of Formula (I).

The present invention relates to stable pharmaceutical composition comprising esomeprazole or pharmaceutically acceptable salts thereof. More particularly, the present invention relates to stable pharmaceutical composition comprising esomeprazole magnesium dihydrate. The present invention further relates to a proces...

The present invention is related to a novel process for the preparation of Azilsartan medoxomil (I), comprising the step of cyclizing Azilsartan amidoxime (XII) to produce Azilsartan medoxomil (I).

The present invention provides a process for the preparation of (15)-2-((5)-2-((5)-2-cyclohexyl-2-(pyrazine-2-carboxamido)acetamido)-3,3-dimethylbutanoyl)octahydro -cyclopenta[c]pyrrole-l-carboxylic acid derivative of formula (I), which comprises: condensing (l1S",3a/?,6aS)-alkyl-2-((5)-2-amino-3,3-dimethylbutanoyl)...

The present invention relates to stable premix formulations for parenteral use and packaging for such formulations. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing premixed injectable formulations which remain stable during the storage period. The ...

The present invention relates to oral solid dosage forms of antiviral agent. More particularly, the present invention relates to oral solid dosage forms of entecavir prepared by dry granulation process.

The present invention relates to oral dosage forms of HIV-1 protease inhibitor. More particularly, the present invention relates to oral dosage forms of atazanavir prepared by wet granulation process using non-aqueous solvent or mixture of aqueous and non-aqueous solvent for granulation.

Pharmaceutical. compositions comprising a" pyn"midine synthesis inhibitof, process of preparation thereof and method of using the same are provided. Particularly the. present invention ‘relates to pharmaceutical compositions comprising téfiflunomide, process of preparation thereof and method to treat patient...

ABSTRACT: Pharmaceutical compositions of anti-viral compounds, process for preparation and method of using the same are provided. Particularly, the present invention relates to chemically stable pharmaceutical compositions of efavirenz, emtricitabine and tenofovir disoproxil fumarate with optionally one or more pha...

The present invention relates to oral solid dosage forms of antiviral agent. More particularly, the present invention relates to oral dosage forms of entecavir prepared by wet granulation process.

AMORPHOUS NALOXEGOL OXALATE AND SOLID DISPERSION OF NALOXEGOL OXALATE ABSTRACT The present invention relates to amorphous solid dispersion of Naloxegol oxalate with one or more pharmaceutically acceptable carriers, process for its preparation and pharmaceutical composition thereof.

The present invention relates to a novel process for preparing a compound of Formula I, which is useful intermediate in the preparation Aliskiren.

The present invention relates to oral dosage forms of HIV-1 protease inhibitor. More particularly, the present invention relates to oral dosage forms of atazanavir prepared by dry process without using solvents such as, dry blending, direct compression or dry granulation.

The present application provides an improved process for racemization of enriched R-(-)-Clopidogrel of Formula I.

The present invention relates to oral solid dosage forms of HIV-1 protease inhibitor. More particularly, the present invention relates to oral dosage forms of atazanavir prepared by melt granulation process.

The present invention relates to a novel process for preparing Aliskiren or its pharmaceutically acceptable salts of Formula I,

The present invention relates to a novel process for preparing a compound of Formula I, which is useful intermediate in the preparation of Aliskiren.

ABSTRACT: Pharmaceutical compositions comprising an atypical antipsychotic as an active agent, process of preparation thereof and method of using the same are provided. Particularly the present invention relates to pharmaceutical compositions comprising lurasidone, process of preparation thereof and method to treat...

Stabilized solid oral pharmaceutical composition comprising angiotensin II receptor blocker(s), process for preparation, and method of using the same are provided. Particularly, the present invention relates to stable pharmaceutical compositions comprising azilsartan or pharmaceutically acceptable salts, esters, hyd...

ABSTRACT The present invention relates to a purification process of Naftopidil (I), comprises dissolving Naftopidil in methanol, followed by treating the solution with carbon at reflux temperature further, isolating pure Naftopidil with reduced content of impurities of formulae IV, V and VI. ...

NOT AVAILABLE

KITS FOR ADMINISTERING BISHOSPHONATES

The present invention relates to pharmaceutical dosage forms of an antidepressant. More particularly, the present invention relates to pharmaceutical dosage forms of Escitalopram oxalate. The present invention also relates to a process for the preparation of pharmaceutical dosage forms of Escitalopram oxalate. ...

The present invention relates to an improved process for preparing Armodafinil of Formula (I), in the presence of an activating agent.

The present invention relates to an improved process for the preparation of Balsalazide of Formula I,

The  present invention relates to an improved process  for the preparation of Palonosetron of Formula I,

The present invention relates to novel pharmaceutically acceptable salts of 7-[(3R)-3- amino-l-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-[l,2,-4]-triazolo [4,3-a]pyrazine of Formula I, or solvates or hydrates thereof.

The technical field of the present invention relates to anti-allergic topical ophthalmic solution of dibenzoxepin derivative. Particularly the present invention relates to an anti-allergic topical ophthalmic solution of olopatadine and its pharmaceutically acceptable salt.

ABSTRACT The present invention relates to a new improved process for the preparation of Cefoxitin of the following formula I Formula I and their pharmaceutical^ acceptable salts.

ABSTARCT The present invention relates to an improved process for the preparation of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-lH-pyrazol-l-yl]benzenesulfonamide of Formula (I),

NOT AVAILABLE

Abstract The present invention relates to controlled release formulations comprising an alpha-adrenergic receptor antagonist. More particularly, the present invention relates to controlled release matrix formulation comprising alfuzosin hydrochloride and a combination of HYDROPHILIC and hydrophobic polymers prepare...

The present invention relates to an extended release formulation of macrolide antibiotic. More particularly, the present invention relates to an extended release formulation of erythromycin derivatives. The present invention also relates to a process for the preparation of extended release formulation containing ery...

The present invention relates to a new crystalline form of l-Cyclopropyl-6-fluoro- 1 ,4-diydro-8-methoxy- 7 -[ (4aS, 7aS)-octahydro-6H-pyrrolo[3,4-b ]pyridin-6-yl]-4- oxo-3-quinoline carboxylic acid hydrochloride herein called as Form A and process for preparing the moxifloxacin crystal form, and the incorporation o...

The present invention provides process for the preparation of crystalline Form B of 7(3-[(Z)-2-(2-amino-4-thiazolyl)-2-hydroxyiminoacetamido]-3-vinyl-3-cephem-4-carboxylic acid of Formula I, wherein Mi+ is selected from Na+, K+, NH4"1"; with acid to produce acid addition salt, followed by treating with base in...

The present invention relates to solid dosage forms of quetiapine. In particular, the invention relates to soled dosage form comprising quetiapine fumatate having defined particle size distribution. The present invention also relates to a process for the preparation of solid dosage forms comprising quetiapine fumara...

The present invention relates to an improved process to prepare Rosuvastatin calcium of Formula I, with good quality.

The present invention relates to an improved process for the preparation of l-benzyl-4-[(5,6-dimethoxy-l-indanon)-2-yl]methylpiperidine hydrochloride of Formula I. which comprises, (i) reacting 5,6-dimethoxy-l-indanone (II), with 1 -benzyl-4-piperidinecarboxaldehyde (III) in presence of base...

Abstract The present invention relates to an extended release formulation of an antiepileptic agent. More particularly, the present invention relates to an extended release formulation of divalproex sodium. The present invention also relates to a process for the preparation of extended release formulation of divalp...

NOT SCANNED

The present invention relates to the one-pot process for the preparation of 8-chloro-6,11-dihydro-ll-(4-piperdinylidene)-5H-benzo[5,6]cyclohepta[l,2-b]pyridine of Formula (I) without isolating the novel intermediate compound 8-chloro-11 -[ 1 -(1 -chloroethoxycarbonyl)-4-piperidinylidene]"6,11 -dihydro-5H-benzo[5,6] ...

The present invention provides an improved process for the preparation of N-[(lR)-l-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan- l-amine hydrochloride  of Formula which comprises:     reducing   3-(3-(trifluoromethyl)phenyl-N-((R)-l-(naphthalen-l-yl)ethyl)prop-2-en-1-amine hydrochloride (Ila), to produ...

The present invention relates to an improved process for the preparation of 3-(3-(trifluoromethyl)phenyI-N-((R)-1 -(naphthalen-1 -yl)ethyl)prop-2-en-1 -amine hydrochloride (unsaturated Cinacalcet hydrochloride) of Formula IIa. The compound of formula (II) is a key intermediate in the preparation of Calcimimetic ag...

The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyI-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-355-dihydroxyhept-6-enoic acid calcium of Formula I,

An improved for the preparation of cephalosporin compounds of Formula I, where R, R one, r two as described in the described in the specification, by reacting novel intermediates of the Formula II, where X, R, R one, R two are as described ...

An improved process for the preparation of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl) methyl] sulfinyl]-l//-benzimidazole of Formula I, Formula I with high enantiomeric excess from racemic mixture.

ABSTRACT The present invention relates to a novel and stereoselective synthetic process for the preparation of optically active cis-nucleoside derivatives of compound of Formula I,

A process for the preparation of famciclovir a compound of Formula I and its intermediates.

The invention relates to an improved process for preparing Tamsulosin hydrochloride of Formula I.

The present invention relates to a novel process for the preparation of Escitalopram, which comprises (i) de-methylating (±)-l-[3-(dimethylamino)propyl]-l-(4-fluorophenyl)-l,3- dihydro-5-isobenzofurancarbonitrile (Formula II) (Citalopram) to produce (±)-1 -[3-(methylamino)propyl]-1 -(4-fluorophenyl)-1,3-di...

The present invention relates to the purification of Telmisartan (I) from a mixture of water immiscible solvent and polar aprotic solvent, which results in the Telmisartan with the purity of above 99.5% by HPLC. Further, the precipitation process of the present invention improves flowability of crystallized product,...

The present invention relates to an improved process for the preparation of [R(E)]-l-[[[ 1-[3-[2-(7 --chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(1-hydroxy-1 methylethyl)phenyl] propyl] thio ]-methyl]cyclopropaneacetic acid, monosodium salt (Montelukast Sodium) of Formula (I), which comprises, condensing 2-(2-(2-(3(S ...

The present invention relates to a new improved process for the preparation of Trandolapril Form II in various solvent and solvent mixtures.

ABSTRACT The present invention relates to an improved process for the preparation of 3-[l-dimethylamino)ethyl]phenol of Formula I which is an useful intermediate in the preparation of (S)-N-ethyl-3-[l-dimethylamino)ethyl]-N-methylphenylcarbamatehydrogen-(2R,3R)-tartrate. ...

The present invention provides an improved process for the preparation of Dutasteride (I) which comprises: (i) reacting 4-aza-5a-androst-l-en-3-one-17p-carboxylic acid (VII),With sulfonic acid anhydride (RSO2)2O in presence of base to produce an intermediate compound of formula(XIII), Wherein R represents C1-6 alkyl...

The present invention provides a method for the preparation ofN-(l-oxopentyl)- N-[[2 "-(1 H-tetrazol-5-yl) [ 1,1 "-biphenyl]-4-yl]methyl]-L-valine (Valsartan) which comprises; treating N-[[2" -( 1-triphenylmethyl-tetrazol- 5-yl)biphenyl-4-yl]methy]- L-valine methyl ester (X)with oxalic acid or its hydrates in a solv...

The invention relates to a process for purification of l-halo-6,6-dimethyl-hept-2-ene-4-yne of formula I

The present application provides an improved process for the preparation of (E)-2-cyano- 3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide(Entacapone), which comprises: (i)   reacting 3,4-dihydroxy-5-nitrobenzaldehyde (II),with cyanoacetic acid (IV) in the presence of catalyst in a solvent to produce ...

The present invention relates to stable oral concentrate composition comprising antidepressant. More particularly, the present invention relates to stable oral concentrate composition comprising sertraline hydrochloride thereof and one or more pharmaceutically acceptable excipients, wherein the composition contains ...

The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium of Formula I.

The present invention relates to extended release dosage form of Anti-Alzheimer's drug. More particularly, the present invention relates to extended release dosage form of galantamine hydrobromide. The present invention also relates to a process for the preparation of extended release dosage form of galantamine hydr...

The present invention relates to an improved process to prepare Rosuvastatin calcium of Formula I, with good quality. Further, the present invention also relates to the new crystalline polymorphic form of Rosuvastatin ethyl ester of Formula II.

The present invention relates to an improved process to prepare Pregabalin of Formula I in one-pot.

The technical field of the present invention relates to stable solid dosage form comprising combination of antihypertensive agents. More particularly, the present invention relates to stable solid dosage form comprising combination of angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker ...

The present invention relates to a process for preparing 7-[(3R)-3- amino-l-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-[l,2,4]-triazolo[4,3-a]pyrazine of Formula I.

The present invention relates to an extended release formulations of macrolide antibiotic. More particularly, the present invention relates to an extended release formulation of erythromycin derivatives. The present invention also relates to a process for the preparation of extended release formulation containing er...

ABSTRACT The present invention relates to an improved process for preparing (2E)-3-[4-(4-fluoroplienyl)-6-isopropyl-2-(N-methyl-N-methylsulfonyIamino)pyrimidin-5-yl]-propenal of formula I, which is an useful intermediate in the preparation of Rosuvastatin.

The present invention relates to an improved process for the preparation of pure 2-[(2-acetylamino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy]-1 -benzyloxy-3-chloropropane (N-acetyl chlorobenzyl ganciclovir) of formula (III), which comprises: (i)  condensing 9-acetyl-2-acety1amino-1,9-dihydro-6H-purin-6-one of formula...

The present invention relates to an improved process for the preparation of 3-[(2- Cyclopentyl-2-hydroxy-2-phenylacetyl)oxy ]-1, I-dimethyl pyrrolidinium bromide of Formula I

The present invention relates to solid dosage forms of bisphosphonic acid derivatives. In particular, the invention relates to solid dosage forms comprising bisphosphonic acid or a pharmaceutically acceptable salt thereof and a salt of monovalent metal ion. The present invention also relates to a process for the pre...

The present invention provides an improved process for the preparation of purine derivative of Formula I.

An improved for preparing olanzapine form I of formula I in the presence of one solvent or a mixture of solvents

The present invention relates to an improved process for preparing (2E)-3-[4-(4- fluoropheny1)-6- isopropy 1-2 -(N -moth y 1- N -methy1sulfonylamino )pyrimidin -5 -Y 1]- propenal of formula (I) which is an intermediate useful in the preparation ofbis[(E)-7-[4-(4-fluorophenyl)-6- isopropyl-2-[ metbyl( metbyls...

ABSTRACT The present invention relates to a novel and stereoselective synthetic process for the preparation of optically active cis-nuelcoside derivatives of compound of Formula I,

The present invention relates to rapidly disintegrating dosage from of olanzapine with no binding agent comprising of about 1-10% olanzapine, about 1-10% of disintegrant, about 70-85% of filler, about 0.4-7% of lubricant.

The technical field of the present invention relates to a solid dosage form comprising angiotensin II receptor blocker (ARB) and diuretic. More particularly, the present invention relates to a solid dosage form comprising telmisartan and hydrochlorothiazide.

The present invention relates to a method of making aripiprazole pharmaceutical composition by wet granulation using organic solvent as granulating liquid. More particularly, the present invention relates to a method of making aripiprazole pharmaceutical composition by wet granulation comprising the steps of: blendi...

The present invention relates to stable oral solution formulation of bisphosphonic acid or its pharmaceutically acceptable salts. More particularly, the present invention relates to stable oral solution formulation of alendronate sodium.

The technical field of the present invention relates to stable oral dosage forms of angiotensin II antagonists. More particularly, the present invention relates to stable oral dosage forms of candesartan cilexetil.

NOT AVAILABLE

The present invention provides an improved process for the, preparation of 3-[3-(trifluoromethyl)phenyl]-2-propen-l-ol (IVb), and 3-[3-(trifluoromethyl)phenyl]-2-propenal (Ilia), The compounds of Formulae Ilia and IVb are key precursors in the preparation of Calcimimetic agent, Cinacalcet hydrochloride of Fo...

The present invention provides an improved process for the preparation of 3-(3-(trifluoromethyl)phenyI-N-((R)-]-(naphthalen-l-yI)ethyI)prop-2-en-I-amine hydrochloride of Formula (Ila), which comprises: (i)   reacting 3-[3-(trifluoromethyl)phenyl]-2-propen-l-ol (IVb), with a reagent containing the leaving group to p...

ABSTARCT The present invention provides an improved process for the preparation of crystalline Form I of (S)-(+)-2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno[3,2-c]pyridine-5-yl)acetic acid methylester hydrogen sulphate of Formula I, which comprises: (i)    preparing a solution of (S)-(+)-Clopidogrel free ba...

The present invention relates to an improved process for preparing (E)-7-[4-(4-fluorophenyl)- 6-isopropl-2-methyslsulfony amino pyrimdin-5-yl 3R,5S-,5-dihydroxyhept-6--enoic acid calcium of Formula I,

The present application provides an improved process for the preparation for the preparation of 4-(l,l-dimethylethyl)-N-[6-halo-5-(2-methoxyphenoxy)-[2,2"- bipyrimidin]-4-yl]benzene-sulfonamide (V11a).

The present invention relates to an improved process for the preparation of highly pure 7-amino-[(4-hydroxyphenyl)acetaniido]cephalosporins of formula I, wherein R represents methyl or 1-propenyl.

NOT AVAILABLE

NOT SCANNED

NOT SCANNED

The present invention relates to oral liquid compositions of antiparkinson drug. More specifically, the present invention relates to oral liquid compositions comprising Ropinirole and pharmaceutically acceptable salts thereof. The present invention also relates to process for preparation of oral liquid pharmaceutica...

The present invention provides an improved process for the preparation of Perindopril of Formula I and its pharmaceutically acceptable salts.

The present invention relates to an improved process for the preparation of 2-n- butyl-3-[[2'-(lH4etrazol-5-yl)(1,1'-biphenyl)-4-yl)-1,3-diazaspiro(4,4)non-1- en-4-one (Irbesartan)

The present invention relates to controlled release formulation comprising an a-adrenoreceptor antagonist. More particularly, the present invention relates to controlled release formulation comprising alfuzosin hydrochloride and a mixture of hydrophilic and hydrophobic polymers.

An improved process for peparing(-)-N-[(trans-4-isopropylcyclohexane)carbonyl]-D-phenylalanine of formula I.

The technical field of the present invention relates to oral dosage forms of bisphosphonic acid or its pharmaceutically acceptable salts. More particularly, the present invention relates to oral dosage forms of bisphosphonic acid or its pharmaceutically acceptable salts prepared by wet granulation process. ...

The present invention relates to an improved process for the preparation of 2-n- butyl-3-[[2'-(IH-tetrazol-5-yl)[I,1 '-biphenyl]-4-yl]-1 ,3-diazaspiro[ 4.4]non-l-en- 4-one (Irbesartan) of Formula (I), which comprises, (i) condensing the compound (XI) with 4-aminomethyl-l, 1 '-biphenyl-2'-carboxamide (XIII) in pre...

The present invention relates to an improved industrial process for the preparation of oxicam derivatives of the Formula I.

The present invention relates to an improved process for the preparation of (2S53aR,7aS)-Octahydro-lH-indole-2-carboxylate hydrochloride of Formula I wherein R represents hydrogen,benzyl and substituted benzyl which comprises subjecting the compound of Formula III to favorsky re-arrangement to obtain an...

An improved process for the preparation of N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydrofuran-2-carboxamide of formula(1) by reacting N1-(4-amino-6,7-dimethoxyquinazolin-2-yl)-N1-methyl propane-1,3-diamine(v) with tetrahydrofuran-2-carboxylic acid or its reactive derivatives ...

The present invention relates to an improved process for the preparation of 7-[4-[4- (2,3-dichlorophenyl)-1 -piperazinyl]butoxy] -3,4-dihydro-2( 1H)-quinolinone of Formula (I).

ABSTRACT The present invention relates to an improved process for the preparation of N-methyl-2-pyridineethanamine (Betahistine) of Formula I,  Formula I by condensing 2-pyridineethanol sulfonate (III) with methylamine,  Formula III wherein R is methyl or p-toluoyl.

The present invention relates to the purification of (2S,3S,5S)-5-amino-2-N,N-dibenzylamino-3-hydroxy-l,6-diphenyIhexane (III) by making its crystalline acid addition salt, which can be used as such to produce Lopinavir /Ritonavir with high purity and yield.

The present invention relates to an improved process for the preparation of Darifenacin hydrobromide of Formula (I). (i) condensing 3-(s)-(-)-(l-carbamoyl-l,l-diphenylmethyl)pyrrolidine (III), or its salt, with a compund of formula XIII in the presence of a base in a solvent, wherein X represents Cl, Br, C1-3 alk...

The present invention relates to a process for the preparation of 2-Ethoxy-4-[2-[[(lS)-2-methyl-l-[2-(l-piperidinyl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid.

The present invention relates to an improved process for the preparation of Escitalopram of the Formula I, which consists of sequential two Grignard reactions on 5-cyanophthalide, isolation of Diol compound of Formula VI as an oxalate salt, resolution of Diol compound and cyclization of resolved compound of Formula ...

The present invention provides an improved process for the preparation of 3-[3-(trifluoromethyl)phenyl]-2-propenal(IIIa), and 3-[3-(trifluoromethyl)phenyl]-2-propen-l-ol (IVb), The compounds of Formulae IIIa and IVb are key precursors in the preparation of Calcimimetic agent, Cinacalcet hydrochloride of Form...

NOT SCANNED

NOT SCANNED

The technical field of the present invention relates to solid dosage form comprising combination of angiotensin II receptor blocker (ARB) and calcium channel blocker (CCB). More particularly, the present invention relates to solid dosage form comprising combination of valsartan and amlodipine.

The present invention relates to an improved process for the preparation of Lacosamide of Formula (I), comprising: O-methylating a compound of Formula (XX); in the presence of a methylating agent and a base to produce Lacosamide of Formula (I).

The present invention provides deprotection of tetrazole biphenyl compound of formula (la) using silica gel supported alkali metal sulfate or cation exchange resin. wherein, R is selected from a group consisting of:

The technical field of the present invention relates to oral dosage forms comprising p-Iactam antibiotic and p-lactamase inhibitor prepared by granulation process. More particularly, the present invention relates to oral dosage forms comprising amoxicillin and clavulanic acid prepared by wet granulation process. ...

The present invention provides an improved process for the preparation of N-[(1R)-1-(1-naphthyi)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-l-amine hydrochloride of Formula (I), which comprises: (i) condensing 3-[3-(trifluoromethyl)phenyl]-2-propenal (Xa), with (R)-l-(l-naphthyl)ethylamine (VII), in the presence o...

The present application provides purification of Bosentan crude by making its crystalline potassium salt, which is further converted to Bosentan (I) with bis-sulfonamide (VIII) and deshydroxyethyl (IX) impurities to less than 0.2% by HPLC analysis. FIG.1

The technical field of the present invention relates to modified release dosage form of p-blocker. The present invention also relates to a process for the preparation of modified release dosage form of p-blocker.

Abstract The present invention relates to stable pharmaceutical dosage forms of combination of antiretroviral agents. More particularly, the present invention relates to stable dosage forms comprising lamivudine, tenofovir disoproxil fumarate and efavirenz.

The present invention relates to the process for the preparation of mixture of crystalline Form I and Form II of 8-chloro-6,11 -dihydro-11 -(4-piperdinylidene)-5H-benzo[5,6]cyclohepta[l,2-b]pyridine of Formula (I) in the ratio between 85:15 and 98:2 by preparing a solution of Desloratadine in a ketonic solvent and a...

The present invention relates to orally disintegrating tablet compositions of antipsychotic agents. More particularly, the present invention relates to orally disintegrating tablet compositions of aripiprazole. The present invention also relates to a process for the preparation of orally disintegrating tablet compos...

The present invention relates to an improved process for preparing crystalline Imipenem monohydrate of Formula I containing Bis-Thienamycin formamidine impurity (Dimer-I) of Formula VIII and Imipenem thienamycin formamidine impurity (Dimer-II) of Formula IX, each less than 0.2%.

An improved process for preparing 11 -cyclopropyl-5,11 -dihydro-4-methyl-6H- dipyrido [3,2-b:2',3'-e] [1,4] diazepin-6-one of formula I

The present invention relates to a novel amorphous form of l-(9H-carbazol-4- yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate (Carvedilol dihydrogen phosphate) of Formula (I), and a process for the preparation thereof.

The present invention provides a process for preparing a stable crystalline solid of Lamivudine polymorphic Form I, which does not change to Form II during storage and pharmaceutical unit operations.

NA

Abstract The present invention relates to a stable solid dosage form comprising an anti-depressant. More particularly, the present invention relates to stable solid dosage form of escitalopram or its salts. The present invention also relates to a process for the preparation of stable solid dosage form of escitalopr...

The present invention relates to novel pharmaceutically acceptable salts selected from benzoate and 4-aminosalicylate salts of 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]- benzazepine (Varenicline) of Formulae I and II. Formula I Formula II

This invention relates to novel injectable pharmaceutical compositions containing florfenicol as the active ingredient with N, N-dimethylacetamide [DMA] either alone or in combination with pyrrolidone solvent as the solvent system and along with other pharmaceutically suitable co-solvent and adjuvaents. ...

The present invention provides a process for the preparation an acid addition salt of N,N-dimethyl-3-chloropropylamine of formula(II), which comprises: reacting N,N-dimethyl-3-phenyl-3-hydroxypropylamine of Formula(IV), with a chlorinating agent in the presence of an acid in an aromatic hydrocarbon solvent and isola...

The technical field of the present invention relates a stable pharmaceutical composition comprising ethinyl estradiol. The present invention also relates to a process for preparation of stable pharmaceutical composition comprising ethinyl estradiol. The present invention further relates to a stable pharmaceutical co...

The present invention relates to stable oral dosage forms of angiotensin II antagonists. More particularly, the present invention relates to a stable oral dosage form comprising candesartan cilexetil, prepared by granulating a blend of excipients comprising adsorbent with a dispersion comprising candesartan and prop...

The present invention relates to a process for the purification of trityl Olmesartan methyl ester of formula (IX), which comprises, crystallizing the compound (IX) to produce pure trityl Olmesartan methyl ester (IX) substantially free of impurities (HI) & (IIIa). The present invention also relates to a process fo...

The present invention relates to an improved process for the purification of Ursodeoxycholic acid (Ursodiol) of Formula (I); which comprises: treating crude Ursodeoxycholic acid with a secondary amine base to produce an amine salt of Ursodeoxycholic acid (VI), which is crystallized from a solvent to produce pure pha...

The present invention relates to a process for preparing Diaminoalcohol, which is a useful intermediate in the preparation of Darunavir of Formula I.

STABLE TOPICAL OPHTHALMIC PRODUCTS The present invention relates to a stable ophthalmic product, and in particular, to the use of packaging materials to obtain stable ophthalmic product. More particularly, the present invention relates to a topical ophthalmic container provided with a label free of varnish. ...

The present invention provides an improved process for the preparation of N -substituted hydroxypyrimidinone carboxamide derivative (Raltegravir) of Formula (I); which comprises hydrogenation of compound of Formula (XVII) with a hydrogenation catalyst to produce compound of Formula (XVIII), which is further reacted...

The present invention relates to an improved process for the preparation of crystalline form Ertapenem sodium of Formula I, which is substantially free of residual solvents.

The present invention relates to novel organic acid salt of Pitavastatin alkyl ester of Formula I. wherein R represents C1-3 alkyl; X represents monobasic or dibasic acid

The present invention relates to stable aqueous oral fonnulation of bisphosphonic acid or its phannaceutically acceptable salts. More particularly, the present invention relates to stable aqueous oral fonnulation of alendronate sodium. The present invention also relates to a process for the preparation of stable aqu...

Pharmaceutical compositions comprising tadalafil or a pharmaceutical^ acceptable salt thereof are provided. The present invention also relates to a process for preparation of pharmaceutical compositions comprising tadalafil or a pharmaceutically acceptable salt thereof. The present invention also relates to method o...

Pharmaceutical composition comprising dronedarone or a pharmaceutical^ acceptable salt thereof is provided. The present invention also relates to a process for preparation of pharmaceutical compositions comprising dronedarone or a pharmaceutical acceptable salt thereof. The present invention also relates to method o...

The present invention relates to an improved process for prepari N, N--dimethyl-5-( 1H-1,2,4-triazol-1 -ylmethyl)-1 H-indole-3-ethanamine of Formula I and its pharmaceutically acceptable salts.

A process for the preparation of cephalosporin compound of the following formula I by the reaction of 7- aminocephalosporanic acid with 2-thiofuroic acid of the following formula III in the presence of baron trifluoride in an organic solvent,such as herein described,and precipitating the reaction p...

The present invention relates to an improved process for the preparation of [R(E)]-I-[[[I-[3-[2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(I-hydroxy-l- methylethyl)phenyl] propyl] thio ]-methyl]cyclopropaneacetic acid, monosodium salt (Montelukast Sodium) of Formula (1), which comprises, condensing 2-(2-(2-(3(S)-(...

The present invention provides an improved process for the preparation of (trans)-4-cyclohexy-L-proline of Formula I Formula I

The present invention relates to a new improved process for the preparation of Cephalothin of the following formula I

The invention relates to a new improved process to prepare amorphous form of [2S-(3R , 4aR*, 8aR*, 2'S*, 3lS*)]-2'.[2'-hydroxy-3'-phenylthiomethyl-4'-aza-5'-(2"methyl-3"-hydroxyphenyl)pentyl]decahydroisoquinoline-3-N-tert-butylcarboxamide methanesulfonate of the following Formula I ...

The present invention relates to a dosage from of bisphosphonic acid derivatives. In particular, the invention relates to a solid dosage form comprising Ibandronic acid or a pharmaceutical acceptable salt therof and silicified microcrystalline cellulose. The present invention also relates to a process for the prepar...

The present invention provides an improved process for the preparation of Bromo formyl Nornarwedine of Formula (I); which comprises oxidative cyclization of compound of Formula (HI) with an oxidizing agent and a base in the presence of a phase transfer catalyst in a solvent to produce Dibromo formyl Nornarwedine...

ABSTARCT A PROCESS FOR THE PREPARATION OF LORCASERIN HYDROCHLORIDE The present invention provides a process for the preparation of crystalline Lorcaserin hydrochloride hemihydrate of Formula (la), which comprises, (i) providing a solution of Lorcaserin base in a solvent; (ii) if water is present, removing water...

Stabilized pharmaceutical compositions comprising a ADP-receptor antagonist as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising ticagrelor, or pharmaceulically acceptable salts, esters, hydrat...

COMPRESSIBLE GRANULATES AND PROCESS FOR PREPARATION THEREOF ABSTRACT The present invention relates to compressible free flowing granulates, process for preparation thereof, and method of using the same for the manufacture of solid dosage forms. The present invention also relates to free flowing directly compressi...

Stabilized pharmaceutical compositions comprising a thrombin inhibitor as an active agent(s), process of preparation and method of using the same are provided. The present invention also relates to stabilized pharmaceutical compositions comprising dabigatran etexilate, or pharmaceutically acceptable salts, esters, h...

The present invention relates to a novel process for preparing amorphous Pitavastatin calcium salt of formula I from C1-4 alkyl ester of Pitavastatin.

The present invention relates to an improved process for the preparation of Modafmil and its enantiomer of Formula I.

ABSTARCT The present invention relates, to a process for the preparation of an acid addition salt of Abacavir (I), which comprises: a) reacting (1 S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)-2-cyclopentene-1 -methanol hydrochloride (III) with cyclopropylamine to produce Abacavir of formula (la), b) treating Abacavir...

NA

The present invention relates to a process for the preparation of pure Tribenoside (I), wherein 1,2-O-isopropylidene-a-D-glucofuranose (II) and 3,5,6-tri-O-benzyl-I,2-0-(l-methylethylidene-a-D-glucofuranose (III) intermediates are purified and used in the preparation of Tribenoside. The present invention is also dir...

The technical field of the present invention relates to topical ophthalmic solution of quinolone antibacterial agent. More particularly, the present invention relates to a container for delivering the topical ophthalmic solution of fluoroquinolone antibacterial agent.

The present invention relates to pharmaceutical compositions comprising combination of sumatriptan and naproxen. More particularly, the present invention relates to pharmaceutical composition comprising sumatriptan, naproxen, a co-processed mixture of starch and lactose and one or more pharmaceutically acceptable ex...

The present invention relates to stable oral composition comprising linaclotide or its pharmaceutically acceptable salts, complexes, polymorphs, hydrates, solvates, enantiomers or racemates, process of preparation thereof and methods of using the same.

The present invention relates to a novel process for the preparation of Ertapenem of formula I, or salt thereof.

ABSTRACT A PROCESS FOR THE PREPARATION OF PHENOXYBENZAMINE The present invention provides a process for the preparation of N-phenoxyisopropyl ethanolamine of Formula (II) and its conversion to Phenoxybenzamine of Formula (I) or pharmaceutically acceptable salts thereof.

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF RISPERIDONE The present invention relates to an improved process for preparation of Risperidone of Formula I, which comprises condensation of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole with 3-(2-chloroethy)-2-methyl-6,7,8,9-tetrahydo-4H-pyrido[1,2-?]pyrimid...

ABSTRACT A PROCESS FOR THE PREPARATION OF TRAMETINIB ACETIC ACID SOLVATE The present invention relates to a process for the preparation of crystalline Form of Trametinib acetic acid solvate (Ia): Formula Ia

ABSTRACT PROCESS FOR THE PREPARATION OF VALACYCLOVIR The present invention relates to a proc improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor. ...

There is provided a process to produce hi~hly pure Sir:i\!astatin of formula! having less than 0 1 air; dimer impurities Which comprises Lactonization ofa compound of the Fonnula II, ,Where Z is H or NH4 in a mixture of acetonitrile and glacial acetic acid under anhydrous conditions at a te...

There is discloseda process to prepare crystaltine form I of Losartan Potassium of Formula IWhich comprises 1. Reacting Losartan Acid or Trilyl Losarton compouud of formula II. 44here 'R' represents hydrogen or tilphenylmethyl (trityl) protecting group with potassium ...

(57) :1 A process tor Lactoruzation to produce Simvastatin at Formula 1 When comprises healing a compound, namely acid or ammonium salt of compound of Formula II Where Z IS M or NH, in an organic solvent selected from xylenes, ethylbenzena and mixtures tnereof at a tempera...

(57) A process is described for producing anhydrous p-form of ((Z)-2-([l(2-amino-4-thiazolyl)[[trans(2S,3S)-2-methyl-4-oxo-l-sulfo-3-azetidir]yl]carbamoyl)methylene]amino oxy]-2-methylpropionic acid (also known as Aztreonam).

The present invention relates to an industrially advantageous method for the purification of Citalopram wherein desmethyl citalopram (Formula II), present in crude Citalopram as an impurity, is methylated to produce pure Citalopram of Formula I. The resulting Citalopram product is isolated as the base or a p...

The present invention describes an industrially advantageous process to prepare highly pure l-methyl-3-phenylpiperazine of Formula I, 1 that makes use of a novel piperazine derivative, 4-benzyl-1 -methyl-2-oxo-3-1 phenylpiperazine, represented by Formula II. The process ...

The present invention provides an industrially advantageous, improved acylation process for the preparation of cephalosporin, cefprozil which comprises the N-acylation of a silylated derivative of 7-amino-3-(1-propen-1-yl)-3-cephem-4-carboxylic acid with D-(-)--2-(p-hydroxyphenyl)glycyl cholride hydrochlorid...

The present invention provides an industrially advantageous, improved acylation process for the preparation of Cephalosporin, Cefprozil which comprises the N-acylation of a silylated derivative of 7-amino-3 -(1 -propen-1 -yl)-3 -cephem-4-carboxylic acid with D-(-)-2-(p-hydroxyphenyl)glycyl chloride hydrochlo...

The present invention relates to an improved process for the preparation of pure Ribavirin of Formula I,from an intermediate Beta-D-ribofuranose derivative of Formula IIWherein R1 represents protecting groups and R2 represents alkyl groupswhich in turn is prepared from triazole derivative a...

The present invention relates to an improved process for the preparation of pure Finasteride of Formula I, which comprises converting dihydrofinasteride to finasteride through novel protected dihydrofinasteride and protected finasteride intermediates.

The present invention relates to stable pharmaceutical composition comprising omeprazole or pharmaceutically acceptable salts thereof. More particularly, the present invention relates to stable pharmaceutical composition comprising omeprazole magnesium. The present invention further relates to a process for the prep...

The present invention relates to a process for the preparation of intermediates of Naloxegol, 3-O-MEM Naloxone, 3-O-MEM-?-Naloxol and 3-O-MEM Naloxegol or pharmaceutically acceptable salt thereof, and their conversion to Naloxegol.

ABSTRACT A PROCESS FOR THE PREPARATION OF DOCOSANOL The present invention provides a process for the preparation of Docosanol (I) by reducing cis-13-Docosenoic acid (V) to obtain Docosanoic acid (III), which is further reduced to obtain Docosanol ...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATIONOF CEFOVECIN SODIUM The present invention relates to an improved process for the preparation of Cefovecin sodium of a Compound of Formula (1). Formula 1

The invention relates to a continuous flow micro mixing reactor technology for the preparation of Pantoprazole, its optically active enantiomers, pharmaceutically acceptable salts, polymorphs, hydrates or solvates thereof.

ABSTRACT A PROCESS FOR THE PREPARATION OF CARIPRAZINE HYDROCHLORIDE The present invention provides a process for the preparation of Cariprazine (Ia) or a pharmaceutically acceptable salt thereof, wherein, N,N-dimethyl-1H-imidazole-1-carboxamide alkyl halide (VII) is reacted with (1r,4r)-4-(2-(4-(2,3-dichloro...

ABSTRACT NOVEL PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE The present invention relates to a process for the preparation of Brexpiprazole of Formula (I) and intermediate thereof.

ABSTRACT A PROCESS FOR THE PREPARATION OF DEFERASIROX The present invention provides an improved process for the preparation of Deferasirox of Formula – I substantially free from ‘hydrazino impurity’ by the condensation of 2-(2-hydrophenyl)-4H-1,3-benzoxazin-4-one of Formula – IV with 4-hydrazino benzoic acid...

A PROCESS FOR THE PREPARATION OF 4-FLUORO-2-METHOXY-5-NITROANILINE The present invention is directed towards a process for the preparation of 4-fluoro-2-methoxy-5-nitroaniline (I) or salts thereof, wherein, 4-fluoro-2-methoxy aniline (III) is protected to obtain N-protected-(4-fluoro-2-methoxy)aniline (VI), which...

ABSTRACT A PROCESS FOR THE PREPARATION OF PENICILLIN G BENZATHINE The present invention provides a process for the preparation of Penicillin G Benzathine with reduced particle size d (0.9) of about from 5 to 50 µm and bulk density in range of about from 0.15 to 0.33 g/ml by using a Homogenizer. ...

ABSTRACT PREPARATION OF SUGAMMADEX OR SALTS THEREOF The present invention relates a process for the preparation of Sugammadex or salts thereof. Further, the present invention relates to a process for the preparation of Sugammadex cesium salt, and its conversion to Sugammadex sodium.

ABSTRACT A PROCESS FOR THE PREPARATION OF LIFITEGRAST The present invention provides dibenzylamine salt of Lifitegrast (XV), and diphenylamine salt of Lifitegrast (XVI) and the use of these salts in the purification process of Lifitegrast (I). The present invention provides a process for the preparation of ...

ABSTRACT PREPARING CRYSTALLINE TIPIRACIL HYDROCHLORIDE The present invention relates to a process for the preparation of Tipiracil hydrochloride crystal III. Further, the present invention relates to pure Tipiracil base having purity greater than about 99.0% by HPLC.

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF ELTROMBOPAG OLAMINE AND ITS INTERMEDIATES The present invention relates to an improved process for the purification of Eltrombopag olamine of compound of formula (2). The present invention also relates to an improved process for the preparation of Eltrombopag ola...

ABSTRACT STABLE DAPTOMYCIN FORMULATIONS FOR PARENTERAL USE The present invention relates to a stable injectable formulation comprising i) Daptomycin or pharmaceutically acceptable salts or solvates thereof and at least one stabilizer selected from the group consisting of Mannitol, Dextran 40, Sorbitol, Hydrox...

ABSTRACT A PROCESS FOR THE PREPARATION OF VIGABATRIN The present invention provides a process for the preparation of vigabatrin of formula (I) with high purity.

ABSTRACT A PROCESS FOR THE PREPARATION OF PENICILLIN G BENZATHINE The present invention provides a process for the preparation of penicillin G benzathine with lecithin of formula (I) with high purity and good yield.

PHARMACEUTICAL COMPOSITION COMPRISING IBUPROFEN AND FAMOTIDINE This invention relates to a stable pharmaceutical composition comprising combination of therapeutically effective amount of ibuprofen and famotidine as an active agents and process of preparation thereof. The invention also relates to the use of said ...

ABSTRACT A PROCESS FOR THE PREPARATION OF PURE AZILSARTAN The present invention provides to a process for the preparation of pure Azilsartan (I) with controlled particle size of D90 is less than 60µm. and D50 is less than 60µm The present invention provides to a process for the preparation of pure Az...

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING BREXPIPRAZOLE AND PROCESS FOR PREPARATION THEREOF The present invention relates to a pharmaceutical composition comprising brexpiprazole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein particle size of ...

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING NALOXEGOL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF The present invention relates to a pharmaceutical composition comprising naloxegol or a pharmaceutically acceptable salt thereof as an active agents and process of preparation thereof. The invention also rela...

ABSTRACT Title: A PROCESS FOR THE PREPARATION OF CLOPIDOGREL BISULPHATE The present invention provides a process for the preparation of Clopidogrel Bisulphate Form – II having reduced particle size d (0.9) of about from 5 to 50 microns by ...

ABSTRACT STABLE CARIPRAZINE FORMULATIONS FOR ORAL USE The present invention relates to stabilized pharmaceutical formulations comprising therapeutically effective amount of Cariprazine premix/solid dispersion, or its pharmaceutically acceptable salts, esters, hydrates and solvates thereof, at least one diluent...

ABSTRACT INJECTABLE PHARMACEUTICAL COMPOSITION COMPRISING EPINEPHRINE AND PROCESS FOR PREPARATION THEREOF The present invention relates to an injectable pharmaceutical composition comprising epinephrine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients, proces...

ABSTRACT A PROCESS FOR THE PREPARATION OF PENICILLIN G BENZATHINE The present invention provides a process for the preparation of Penicillin G Benzathine with lecithin coating having reduced particle size d (0.9) of about from 5 to 50 µm by using...

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING ANTIHISTAMINE AND DECONGESTANT, PROCESS OF PREPARATION AND USE THEREOF The present invention relates to a layered composition of fexofenadine hydrochloride and pseudoephedrine hydrochloride and one or more pharmaceutically acceptable excipient for seasonal allergi...

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING ESLICARBAZEPINE AND PROCESS FOR PREPARATION THEREOF The present invention relates to pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable salts, in combination with suitable excipients, in particular a binder, disintegrant and a...

AN IMPROVED PROCESS FOR THE PREPARATION OF PONATINIB OR SALT THEREOF The present invention relates to an improved process for the preparation of Ponatinib or its pharmaceutically acceptable salt, which comprises activation of Ethynyl toluicacid intermediate with amide coupling agent to obtain an Active amide deri...

ABSTRACT IMPROVED PROCESS FOR THE PREPARATION OF BENOXAPROFEN AND ITS INTERMEDIATE The present invention relates to an improved process for the preparation of Benoxaprofen of formula (I) and its intermediate (V) thereof.

ABSTRACT A PROCESS FOR PREPARING CRYSTAL OF SITAGLIPTIN HYDROCHLORIDE The present invention relates to a process for preparing Sitagliptin hydrochloride monohydrate crystals having bulk density at least about 0.2 gm/ml.

ABSTRACT A PROCESS FOR THE PREPARATION OF AMORPHOUS EDETATE CALCIUM DISODIUM The present invention relates to a process for preparing amorphous Edetate calcium disodium by using lyophilization technique.

ABSTRACT A PROCESS FOR THE PREPARATION OF BRIVUDINE The present invention relates to a novel compound 2’-deoxyuridine of Formula (II) and its conversion to Brivudine of Formula (I) or pharmaceutically acceptable salts thereof. , , Wherein, R and R’ are same or different selected from hydroxy protecti...

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING ELUXADOLINE, PROCESS OF PREPARATION AND USE THEREOF The present invention relates to oral pharmaceutical compositions comprising eluxadoline or a prodrug or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, and p...

ABSTRACT The present invention relates to a pharmaceutical composition comprising amorphous sacubitril valsartan trisodium complex with copovidone and poloxamer and a process for preparing the composition thereof. The present invention also relates to a pharmaceutical composition comprising sacubitril valsartan t...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF INTERMEDIATE USED IN THE PREPARATION OF ELTROMBOPAG The present invention relates to an improved process for the preparation of Eltrombopag (2) and its intermediates, which are substantially free of N-methyl impurity.

ABSTRACT A PROCESS FOR THE PREPARATION OF TEZACAFTOR The present invention relates to a novel compound of Formula – IIa and its use in the preparation of Tezacaftor of Formula–I , wherein, R is selected from a hydroxy protecting groups.

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF TAFAMIDIS MEGLUMINE The present invention relates to an improved process for the preparation of Tafamidis of a compound of formula (1) and Tafamidis meglumine of a compound of formula (2) and its intermediates with high purity and good yield. Formula 1 Fo...

ABSTRACT AN IMPROVED PURIFICATION PROCESS FOR THE PREPARATION OF ERTUGLIFLOZIN AND ERTUGLIFLOZIN L-PYROGLUTAMIC ACID CO-CRYSTAL The present invention relates to an improved purification process for the preparation of Ertugliflozin (I) and its further conversion to Ertugliflozin L-pyroglutamic acid (L-PGA) co-cryst...

ABSTRACT ETELCALCETIDE FORMULATIONS FOR PARENTERAL USE The present invention relates to a stable injectable formulation comprising i) Etelcalcetide or pharmaceutically acceptable salts or solvates thereof; ii) a buffering agent preferably selected from group consisting of L tartaric acid, Benzene sulfonic acid...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF 4-OXOISOTRETINOIN The present invention relates to an improved process for the preparation of 4-Oxoisotretinoin and purification process of 4-Oxoisotretinoin (I). I

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING AZILSARTAN MEDOXOMIL OR COMBINATION THEREOF This invention relates to solid oral pharmaceutical composition comprising azilsartan medoxomil or a pharmaceutically acceptable salt and combination thereof. In particular said invention relates to pharmaceutical compos...

ABSTRACT A PROCESS FOR THE PREPARATION OF L-GLUTAMINE The present invention relates to a process for the preparation of L-Glutamine of Formula I.

ABSTRACT NOVEL CRYSTALLINE FORMS OF TAFAMIDIS AND PROCESS FOR THE PREPARATION THEREOF The present invention relates to novel Tafamidis polyethylene glycol co-crystal and process for the preparation thereof. The present invention also relates to novel crystalline form of Tafamidis and process for preparation...

ABSTRACT A PROCESS FOR THE PREPARATION OF ELEXACAFTOR The present invention relates to a process for the preparation of amorphous Elexacaftor of Formula-I.

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF UPADACITINIB The present invention relates to an improved process for the preparation of highly pure Upadacitinib via novel crystalline salts of intermediates. Formula (1)

ABSTRACT OXCARBAZEPINE MODIFIED-RELEASE FORMULATIONS FOR ORAL USE The invention relates to a solid oral modified-release pharmaceutical composition comprising Oxcarbazepine or salts thereof, wherein said composition does not contain pH-dependent soluble polymer. In particular, the present invention relates ...

EXTENDED RELEASE COMPOSITIONS OF PSEUDOEPHEDRINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ABSTRACT This invention relates to dosage forms comprising pseudoephedrine or a salt thereof, for extended-release up to 24 hours, and process of making such dosage forms. This invention provides a non-osmotic exte...

ABSTRACT PROCESS FOR THE PREPARATION DL-PROLINE CO-CRYSTAL OF DAPAGLIFLOZIN The present invention relates to a prOCess for the preparation of Dapagliflozin DL-Proline éo-crystal and its use in the preparation/purification of Dapagliflozin.

ABSTRACT VASOPRESSIN FORMULATIONS FOR PARENTERAL USE The present invention relates to a stable injectable formulation of Vasopressin comprising i) Vasopressin or a pharmaceutically-acceptable salt thereof, ii) a buffering agent that stabilizes or maintains the pH can be selected from Acetic acid, Citric acid...

ABSTRACT CANAGLIFLOZIN SUBSTANTIALLY FREE OF HYDROPEROXIDE IMPURITY The present invention relates to a process for the preparation of Canagliflozin which is substantially free of hydroperoxide impurity.

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING CLEVIDIPINE AND PROCESS FOR PREPARATION THEREOF The present invention relates to injectable oil in water pharmaceutical composition comprising effective amount of clevidipine or a pharmaceutically acceptable salt or ester as an active agent and process of preparat...

ABSTRACT LIRAGLUTIDE FORMULATIONS FOR PARENTERAL USE The present invention relates to a stable injectable formulation comprising i) Liraglutide or a pharmaceutically-acceptable salt thereof, ii) a buffering agent preferably selected from group consisting of CAPS (N-cyclohexyl-3-aminopropanesulfonic acid) buf...

A PROCESS FOR THE PREPARATION OF PENICILLIN G BENZATHINE The present invention provides a one-pot synthesis for the preparation of 4,6-ditert-butyl-2-bromo-3-nitrophenyl methyl carbonate of Formula – IV. The present invention also provides an improved process for the preparation of 2,4-di-tert-butyl-5-amino ph...

ABSTRACT PEN INJECTOR WITH DRIVE MEMBER AND REDUCER ARM A portable self-administrable medication delivery device with “End of Life” feature includes a housing, a drive member within said housing, a locking element and a medicine filled container. The device further provides a “Partial Dose Prevention” feature ...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF PURE PYRIMETHAMINE The present invention relates to an improved process for the preparation of pure Pyrimethamine. The present invention also relates to a process for the preparation of intermediate of Pyrimethamine, 2-(4-chlorophenyl)-2-(-2-ethyl-1,3-dioxolan...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF BENOXAPROFEN The present invention relates to an improved process for the preparation of Benoxaprofen of formula (I) and intermediates (II) & (IV) thereof.

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING PIMAVANSERIN, PROCESS OF PREPARATION AND USE THEREOF The present invention relates to prepare pharmaceutical compositions comprising pimavanserin or a pharmaceutically acceptable salt thereof, processes for manufacturing said pharmaceutical compositions comprising...

ABSTRACT A PROCESS FOR THE PREPARATION OF APALUTAMIDE The present invention relates to an improved process for the preparation of compound of Formula – II and its conversion to apalutamide of Formula – I or pharmaceutically acceptable salts thereof.

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING BRIVARACETAM AND PROCESS FOR PREPARATION THEREOF The present invention relates to pharmaceutical composition comprising brivaracetam or its pharmaceutically acceptable salts, in combination with pharmaceutically acceptable excipient(s). The invention also relates ...

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING SAFINAMIDE AND PROCESS FOR PREPARATION THEREOF The present invention relates to pharmaceutical composition comprising safinamide or its pharmaceutically acceptable salts, in combination with suitable excipients with specific percentages. The invention also relates...

ABSTRACT AN IMPROVED PROCESS FOR THE PURIFICATION OF L-GLUTAMINE The present invention relates to an improved process for the purification of L-Glutamine of Formula I having specific bulk density and Hausner ratio.

ABSTRACT Title: A PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE The present invention relates to an improved process for the preparation of sterile Aripiprazole Hydrate A having a mean particle size less than about 50 µm.

ABSTRACT A PROCESS FOR THE PURIFICATION OF BARNIDIPINE HYDROCHLORIDE The present invention relates to a process for the purification of Barnidipine hydrochloride of Formula I. Formula I

ABSTRACT PHARMACEUTICAL COMPOSITIONS OF ELAGOLIX OR ACCEPTABLE SALTS THEREOF This present invention relates to pharmaceutical composition comprising elagolix or its pharmaceutically acceptable salts thereof and suitable pharmaceutical excipients comprising antigelling agent, solubilizer and filler. The inventi...

ABSTRACT PHARMACEUTICAL COMPOSITION COMPRISING DEUTETRABENAZINE AND PROCESS FOR PREPARATION THEREOF This present invention relates to pharmaceutical composition comprising Deutetrabenazine. The invention also relates to the methods of preparation of the composition having improved stability and dissolution pro...

ABSTRACT STABLE PEPTIDE FORMULATIONS FOR ORAL USE The invention relates to stable pharmaceutical formulation useful for the oral administration comprising a peptide or protein drug and a permeation enhancer. In particular, the invention relates to stabilized pharmaceutical formulations comprising GLP-1 recepto...

ABSTRACT A PROCESS FOR THE ENANTIOSELECTIVE SYNTHESIS OF (R)-ß-AMINO BUTYRIC ACID The present invention relates to a newly identified aspartate ammonia lyase (AAL) from Ureibacillus microorganism and its variants thereof. The invention also relates to nucleotides related to the AAL and it’s variant. The inventio...

ABSTRACT A PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE SECONDARY ALCOHOLS The present invention provides a process for the preparation of optically active secondary alcohols of formula I; Formula I wherein * is an optically active (R) or (S)- configuration; n is 0 to 5; R1 is saturated or unsa...

ABSTRACT A NOVEL PROCESS FOR THE PREPARATION OF 3CL PROTEASE INHIBITOR (NIRMATRELVIR) The present invention relates to a novel process for the preparation of 3CL protease inhibitor; Nirmatrelvir of Formula (X) or its solvates, hydrates and co-crystals thereof, which is industrially viable. Formula (X) ...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF BARICITINIB The present invention relates to an improved process for the preparation of Baricitinib. Formula 1

ABSTRACT A PROCESS FOR THE PREPARATION OF SARECYCLINE The present invention relates to a simple and cost effective process for the purification of Sancycline of Formula – II. Sancycline of Formula – II is the key starting material of Sarecycline of Formula – I or pharmaceutically acceptable salt thereof...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF PEMETREXED AND ITS INTERMEDIATES The present invention relates to an improved process for the preparation of Pemetrexed (1) and Pemetrexed disodium salt (2). Formula 1 Formula 2

PHARMACEUTICAL COMPOSITIONS OF UBROGEPANT AND PROCESS FOR PREPARATION THEREOF ABSTRACT The present invention relates to a stable immediate release tablet compositions of Ubrogepant and one or more pharmaceutically acceptable excipients and a process for preparation thereof.

ABSTRACT A PROCESS FOR THE PREPARATION OF UBROGEPANT The present invention relates to a simple and cost effective process for the preparation of Lactam compound of Formula – II or pharmaceutically acceptable salt thereof. Lactam compound of Formula – II is the key advanced intermediate of Ubrogepant of ...

ABSTRACT A PROCESS FOR PARTICLE SIZE REDUCTION OF HYDROCHLOROTHIAZIDE The present invention relates to a process for particle size reduction of Hydrochlorothiazide with reduced nitrosamine impurity utilizing colloidal milling.

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF (S)-BENOXAPROFEN The invention relates to a process for the preparation of (S)-Benoxaprofen by resolution of Racemic Benoxaprofen by a general, efficient and cost effective chiral reagent and solvents and it is feasible at commercial level. ...

ABSTRACT A PROCESS FOR THE PREPARATION OF LEMBOREXANT INTERMEDIATE The present invention relates to a process for the preparation of salt of cyclopropane pyrimidine carboxylic acid of Formula II, having purity >95 % by HPLC, which is a useful intermediate in the preparation of Lemborexant of Formula I. ...

ABSTRACT PHARMACEUTICAL COMPOSITIONS OF SIPONIMOD OR ACCEPTABLE SALTS THEREOF This invention relates to stable pharmaceutical composition comprising siponimod or its pharmaceutically acceptable salts, esters, solvates, derivatives, amides, polymorphs, enantiomers, prodrugs, analogues, active metabolites or mix...

ABSTRACT STABLE LIQUID DOSAGE FORM OF EDARAVONE AND ITS PREPARATION THEREOF The present invention relates to process of making storage-stable liquid edaravone formulations for parenteral use and packaging such storage-stable liquid formulations for a desired time duration in a glass vial. ...

ABSTRACT IMMEDIATE RELEASE FORMULATIONS OF DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE The present invention relates to immediate release pharmaceutical formulations comprising of dapagliflozin and metformin hydrochloride and a process of making such formulations.

ABSTRACT An improved process for the preparation of crystalline Encorafenib The present invention relates to an improved process for the preparation of crystalline Encorafenib having purity greater than 99.0% by using ketone, ester, or mixture of solvents thereof.

ABSTRACT NOVEL CRYSTALLINE FORM OF ELIGLUSTAT TARTRATE (1:1) AND PROCESS FOR THE PREPARATION THEREOF The present invention relates to the novel crystalline form of Eliglustat Tartrate (1:1) and process for the preparation thereof.

ABSTRACT An improved process for the preparation of intermediates used in the preparation of Revefenacin The present invention relates to an improved process for the preparation of intermediates, Biphenyl piperidine carbamate and Biphenyl piperidine N-(methylamino) ethyl carbamate, and their conversion to Reve...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF TRIHEPTANOIN The present invention relates to an improved process of Triheptanoin, which is cost-effective, stable and viable at commercial scale. Formula I

ABSTRACT NOVEL CRYSTALLINE FORMS OF ACORAMIDIS HYDROCHLORIDE AND PROCESSES FOR PREPARATION The present invention relates to Benzyl alcohol solvate of Acoramidis hydrochloride, designated as crystalline Acoramidis hydrochloride Form ACR-1 and DMSO solvate of Acoramidis hydrochloride, designated as crystalline A...

ABSTRACT PHARMACEUTICAL COMPOSITIONS OF RIMEGEPANT The present invention relates to rapidly disintegrating pharmaceutical composition comprising Rimegepant or pharmaceutically acceptable salt thereof, and processes for manufacture thereof.

ABSTRACT CRYSTALLINE FORMS OF ISAVUCONAZONIUM SULFATE The present invention provides novel, pure and stable crystalline forms of Isavuconazonium sulfate, a process for the preparation thereof and a pharmaceutical composition containing crystalline forms of Isavuconazonium sulfate.

ABSTRACT CRYSTALLINE HYDRATED FORMS OF APABETALONE The present invention provides novel crystalline hydrated forms of Apabetalone viz., crystalline form of Apabetalone hydrate (Form APB-4) and crystalline form of Apabetalone hydrate (Form APB-8), processes for their preparation, pharmaceutical composition and ...

ABSTRACT A PROCESS FOR THE PREPARATION OF ISAVUCONAZONIUM INTERMEDIATE The present invention provides a process for the preparation of N-methyl-N-(3-[((N-tert-butoxycarbonyl-N-methylamino)acetoxy)methyl)pyridin-2-yl]carbamic acid 1-chloroethyl ester compound of Formula (I), and one pot process for the preparati...

ABSTRACT PHARMACEUTICAL COMPOSITIONS OF LUMATEPERONE The present disclosure relates to pharmaceutical composition comprising Lumateperone or pharmaceutically acceptable salt form and, processes for manufacture thereof.

ABSTRACT A PROCESS FOR THE PREPARATION OF BELUMOSUDIL AND ITS INTERMEDIATES The present invention relates to a process for the preparation of Belumosudil or pharmaceutically acceptable salts thereof. Further, the present invention relates to Belumosudil novel intermediate of Formula-V and its process for the p...

ABSTRACT SOLID STATE FORM OF MAVACAMTEN The present invention relates to a solid-state form of Mavacamten, processes for preparing thereof and pharmaceutical composition thereof. In particular, the present invention relates to a crystalline MAV-2 of Mavacamten, the process and composition thereof. ...

ABSTRACT CRYSTALLINE FORMS OF APABETALONE The present invention provides novel crystalline forms of Apabetalone or solvates viz., crystalline form of Apabetalone (Form APB-5), crystalline form of Apabetalone (APB-12) and crystalline propionic acid solvate of Apabetalone (Form APB-2), and processes for their pr...

ABSTRACT A PROCESS FOR THE PREPARATION OF KEY INTERMEDIATE OF CGRP RECEPTOR ANTAGONISTS The present invention relates to a simple and cost effective process for the preparation of substantially pure compound of Formula – IV. The compound of Formula – IV is a key intermediate in the preparation of CGRP (Cal...

ABSTRACT AN IMPROVED PROCESS FOR THE PREPARATION OF BRIVARACETAM The present invention relates to an improved process for the preparation of Brivaracetam via co-crystal with tartaric acid.

ABSTRACT A PROCESS FOR THE PREPARATION OF AMPICILLIN TRIHYDRATE The present invention provides a process for the preparation of Ampicillin trihydrate with lecithin coated having reduced particle size by using a Double planetary mixer.

ABSTRACT NOVEL CRYSTALLINE FORM OF LENACAPAVIR SODIUM AND PROCESSES FOR ITS PREPARATION The present invention provides a novel crystalline form of Lenacapavir sodium and a process for its preparation. The crystalline form of Lenacapavir sodium of the present invention herein designated as Form LEA-1 of Lenacapavir...

ABSTRACT NOVEL CRYSTALLINE FORMS OF MITAPIVAT SULFATE AND PROCESSES FOR PREPARATION The present invention relates to novel polymorphs of Mitapivat sulfate, designated as crystalline Mitapivat sulfate Form MIP-1 and MIP-2 and processes for the preparation thereof.